We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

By LabMedica International staff writers
Posted on 30 Sep 2026

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. More...

Current analytical methods can be complex, time-consuming, and dependent on specialized personnel, limiting their use for rapid onsite screening. To simplify this type of analysis, new findings demonstrate a laser-based approach that detects disease-associated odor signatures from simple swab samples.

The Fraunhofer Institute for Integrated Circuits IIS (Erlangen, Germany) and the Technical University of Dresden tested laser-based photoacoustic spectroscopy for detecting volatile organic compound patterns linked to disease. The measurement system developed at Fraunhofer IIS uses widely tunable quantum cascade lasers and a sensitive photoacoustic detector. The system generates characteristic spectral fingerprints of volatile organic compounds from swab samples taken from the anterior nasal cavity, navel, and outer ear, with nasal swabs described as particularly promising.

The proof-of-concept study was conducted under controlled laboratory conditions using participants randomly selected from the large-scale SMELLODI study. The cohort included 24 participants: six healthy controls, six people with Parkinson’s disease, six people with COVID-19, and six people with other conditions. Additional measurements taken two weeks later from three participants with Parkinson’s disease provided initial evidence that the results were stable over time. Statistical analysis also showed that the measurement scope could be significantly reduced without losing relevant information.

The study found differences between samples from healthy individuals and samples from people with Parkinson’s disease, COVID-19, and other diseases. The results were published in Scientific Reports under the title “Detection of disease-associated VOC signatures with laser-based photoacoustic spectroscopy (LPAS).”

Fraunhofer IIS developed the experimental setup, performed laboratory measurements, and conducted statistical analysis, while the Technical University of Dresden contributed medical and clinical expertise and coordinated recruitment, diagnosis, and sample collection. The approach is not yet a substitute for medical diagnosis, and larger studies involving more diverse participants under real-world conditions are needed before clinical use.

Related Links
Fraunhofer IIS
Technical University of Dresden


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.